

Anti-Siglec-2/CD22 Antibody (Pinatuzumab vedotin)

Introduction

Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S) is an antibody-drug conjugate (ADC) CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte adhesion molecule, BL-CAM, Leu-14) Antibodies and cytotoxic agents Monomethyl auristatin E (MMAE) conjugated via a maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.

Product parameters

Alternative Names	RG7593, DCDT2980S, 10F4
Target Accession	P20273
Target	Siglec-2 / CD22
CAS number	1313706-14-7
Molecular Weight	151.97 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The drug-to-antibody ratio (DAR) of the Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) is 4.3.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

